Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961385 | 0.91 | PDE4D (0.86) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6836484 | 0.85 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6836702 | 0.84 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL7050561 | 0.83 | PDE4D (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6837689 | 0.82 | RAB9A (0.53) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6837653 | 0.81 | SMN1; SMN2 (0.60) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6839328 | 0.81 | SMN1; SMN2 (0.62) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6836442 | 0.79 | PDE4D (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6839420 | 0.79 | RAB9A (0.55) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL8333880 | 0.78 | PDE4D (1.00) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | PDE4A 4879/4885PDE4B 4877/4885PDE4C 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.